Bank Julius Baer & Co. Ltd Zurich Acquires 2,770 Shares of Eli Lilly and Company (NYSE:LLY)

Bank Julius Baer & Co. Ltd Zurich boosted its holdings in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 116.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,158 shares of the company’s stock after acquiring an additional 2,770 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Eli Lilly and were worth $1,668,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Benjamin Edwards Inc. grew its holdings in Eli Lilly and by 0.7% during the 3rd quarter. Benjamin Edwards Inc. now owns 3,836 shares of the company’s stock worth $1,240,000 after acquiring an additional 28 shares during the last quarter. Moloney Securities Asset Management LLC grew its holdings in Eli Lilly and by 0.6% during the 3rd quarter. Moloney Securities Asset Management LLC now owns 5,000 shares of the company’s stock worth $1,617,000 after acquiring an additional 28 shares during the last quarter. Auxano Advisors LLC lifted its position in shares of Eli Lilly and by 2.1% in the 3rd quarter. Auxano Advisors LLC now owns 1,385 shares of the company’s stock worth $448,000 after purchasing an additional 28 shares during the period. Avidian Wealth Solutions LLC lifted its position in shares of Eli Lilly and by 0.4% in the 3rd quarter. Avidian Wealth Solutions LLC now owns 7,354 shares of the company’s stock worth $2,378,000 after purchasing an additional 30 shares during the period. Finally, Cahaba Wealth Management Inc. lifted its position in shares of Eli Lilly and by 1.6% in the 2nd quarter. Cahaba Wealth Management Inc. now owns 1,945 shares of the company’s stock worth $630,000 after purchasing an additional 31 shares during the period. 82.13% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on LLY shares. Morgan Stanley dropped their price target on shares of Eli Lilly and from $446.00 to $440.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 14th. Barclays boosted their price target on shares of Eli Lilly and from $395.00 to $400.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 3rd. Wells Fargo & Company boosted their price target on shares of Eli Lilly and from $365.00 to $375.00 and gave the stock an “equal weight” rating in a research report on Thursday, December 8th. StockNews.com started coverage on shares of Eli Lilly and in a research report on Wednesday, October 12th. They set a “buy” rating on the stock. Finally, Cowen boosted their target price on shares of Eli Lilly and from $390.00 to $430.00 and gave the company an “outperform” rating in a research report on Monday, December 5th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Eli Lilly and presently has an average rating of “Moderate Buy” and an average target price of $384.11.

Eli Lilly and Stock Performance

Shares of LLY stock opened at $346.39 on Wednesday. The firm has a market capitalization of $329.13 billion, a PE ratio of 52.01, a price-to-earnings-growth ratio of 2.12 and a beta of 0.36. The firm has a fifty day simple moving average of $361.80 and a two-hundred day simple moving average of $338.46. The company has a current ratio of 1.13, a quick ratio of 0.88 and a debt-to-equity ratio of 1.39. Eli Lilly and Company has a 12 month low of $231.87 and a 12 month high of $384.44.

Eli Lilly and (NYSE:LLYGet Rating) last announced its quarterly earnings results on Tuesday, November 1st. The company reported $1.98 EPS for the quarter, beating analysts’ consensus estimates of $1.97 by $0.01. The business had revenue of $6.94 billion during the quarter, compared to analyst estimates of $6.91 billion. Eli Lilly and had a net margin of 20.63% and a return on equity of 80.80%. Analysts forecast that Eli Lilly and Company will post 7.77 EPS for the current fiscal year.

Eli Lilly and Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 10th. Stockholders of record on Wednesday, February 15th will be paid a $1.13 dividend. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.98. The ex-dividend date is Tuesday, February 14th. This represents a $4.52 annualized dividend and a dividend yield of 1.30%. Eli Lilly and’s dividend payout ratio is presently 58.86%.

Insider Transactions at Eli Lilly and

In other news, major shareholder Lilly Endowment Inc sold 49,089 shares of the company’s stock in a transaction on Friday, December 2nd. The shares were sold at an average price of $372.88, for a total value of $18,304,306.32. Following the completion of the sale, the insider now owns 102,948,810 shares in the company, valued at approximately $38,387,552,272.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, major shareholder Acquisition Corp Kearny purchased 29,992,668 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, November 30th. The stock was bought at an average price of $12.50 per share, for a total transaction of $374,908,350.00. Following the completion of the transaction, the insider now owns 100 shares in the company, valued at $1,250. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 49,089 shares of the stock in a transaction dated Friday, December 2nd. The shares were sold at an average price of $372.88, for a total transaction of $18,304,306.32. Following the transaction, the insider now owns 102,948,810 shares of the company’s stock, valued at approximately $38,387,552,272.80. The disclosure for this sale can be found here. Insiders sold a total of 120,141 shares of company stock worth $44,151,279 in the last quarter. 0.12% of the stock is currently owned by corporate insiders.

About Eli Lilly and

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.